دورية أكاديمية
أعرض في EDS

Prospective Cohort Real-World Study on Neuroendocrine Tumor Patient's Quality of Life During Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE.

التفاصيل البيبلوغرافية
العنوان: Prospective Cohort Real-World Study on Neuroendocrine Tumor Patient's Quality of Life During Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE.
المؤلفون: Ramim JE, Matheos de Lima BA; From the Nuclear Medicine Section., Bulzico DA; From the Nuclear Medicine Section., Pujatti PB; From the Nuclear Medicine Section., Bergmann A; Clinical Epidemiology Program, National Cancer Institute (INCA), Rio de Janeiro, Brazil.
المصدر: Pancreas [Pancreas] 2022 Aug 01; Vol. 51 (7), pp. 784-789.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 8608542 Publication Model: Print Cited Medium: Internet ISSN: 1536-4828 (Electronic) Linking ISSN: 08853177 NLM ISO Abbreviation: Pancreas Subsets: MEDLINE
أسماء مطبوعة: Publication: Hagerstown, MD : Lippincott Williams & Wilkins
Original Publication: [New York, N.Y.] : Raven Press, [c1986-
مواضيع طبية MeSH: Neuroendocrine Tumors*/radiotherapy , Neuroendocrine Tumors*/pathology, Adult ; Humans ; Middle Aged ; Prospective Studies ; Quality of Life ; Radioisotopes/therapeutic use ; Receptors, Peptide ; Aged
مستخلص: Objective: The aim of this study was to report lutetium-177 (177Lu)-DOTATATE radionuclide therapy from a patient perspective and their health-related quality of life.
Methods: This prospective cohort study, including adult patients treated with 177Lu-DOTATATE. At the beginning of the follow-up (T1), socioeconomic and clinical information was collected, and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaires C30-v3 and GI.NET21 were applied. Follow-up was performed at the third cycle (T2) and 3 months after the end of treatment (T3). Student t test for paired samples was used to compare quality of life at T1, T2, and T3.
Results: Thirty-eight patients with stage IV disease and mean age of 52.54 (standard deviation, 12.49) years were included. The most prevalent site was the gastrointestinal tract (39.7%). Global health improved between T2 and T3 (P = 0.022) and T1 and T3 (P = 0.038). Functional scales did not indicate significant changes between the periods. Regarding symptoms, significant improvements in nausea and vomiting and gastrointestinal symptoms were observed between T2 and T3 (P = 0.012 and 0.029) and T1 and T3 (P = 0.012 and 0.011), respectively.
Conclusions: 177Lu-DOTATATE therapy improved global health and reduced disease-related symptoms in NET patients, positively impacting health-related quality of life.
Competing Interests: The authors declare no conflict of interest.
(Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.)
References: Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol . 2017;3:1335–1342.
Kulke MH, Benson AB, Bergsland E, et al. Neuroendocrine tumors. J Natl Compr Canc Netw . 2012;10:724–764.
Singh S, Granberg D, Wolin E, et al. Patient-reported burden of a neuroendocrine tumor (NET) diagnosis: results from the first global survey of patients with NETs. J Glob Oncol . 2017;3:43–53.
Boudreaux JP, Klimstra DS, Hassan MM, et al. The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the jejunum, ileum, appendix, and cecum. Pancreas . 2010;39:753–766.
Kam BLR, Teunissen JJM, Krenning EP, et al. Lutetium-labelled peptides for therapy of neuroendocrine tumours. Eur J Nucl Med Mol Imaging . 2012;39(suppl 1):S103–S112.
Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of 177 Lu-DOTATATE for midgut neuroendocrine tumors. N Engl J Med . 2017;376:125–135.
Khan S, Krenning EP, van Essen M, et al. Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [ 177 Lu-DOTA0,Tyr3]octreotate. J Nucl Med . 2011;52:1361–1368.
Strosberg J, Wolin E, Chasen B, et al. Health-related quality of life in patients with progressive midgut neuroendocrine tumors treated with 177 Lu-DOTATATE in the phase III NETTER-1 trial. J Clin Oncol . 2018;36:2578–2584.
Bodei L, Mueller-Brand J, Baum RP, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging . 2013;40:800–816.
Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst . 1993;85:365–376.
Fayers PM. Interpreting quality of life data: population-based reference data for the EORTC QLQ-C30. Eur J Cancer . 2001;37:1331–1334.
Yadegarfar G, Friend L, Jones L, et al. Validation of the EORTC QLQ-GINET21 questionnaire for assessing quality of life of patients with gastrointestinal neuroendocrine tumours. Br J Cancer . 2013;108:301–310.
Modlin IM, Sandor A. An analysis of 8305 cases of carcinoid tumors. Cancer . 1997;79:813–829.
Beaumont JL, Cella D, Phan AT, et al. Comparison of health-related quality of life in patients with neuroendocrine tumors with quality of life in the general US population. Pancreas . 2012;41:461–466.
Halperin DM, Huynh L, Beaumont JL, et al. Assessment of change in quality of life, carcinoid syndrome symptoms and healthcare resource utilization in patients with carcinoid syndrome. BMC Cancer . 2019;19:274.
Halperin DM, Shen C, Dasari A, et al. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet Oncol . 2017;18:525–534.
Pavel M, O'Toole D, Costa F, et al. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology . 2016;103:172–185.
Pavel M, Öberg K, Falconi M, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol . 2020;31:844–860.
Sowa-Staszczak A, Pach D, Chrzan R, et al. Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NETs). Eur J Nucl Med Mol Imaging . 2011;38:1669–1674.
Van Vliet EI, van Eijck CH, de Krijger RR, et al. Neoadjuvant treatment of nonfunctioning pancreatic neuroendocrine tumors with [ 177 Lu-DOTA0,Tyr3]octreotate. J Nucl Med . 2015;56:1647–1653.
Pach D, Sowa-Staszczak A, Kunikowska J, et al. Repeated cycles of peptide receptor radionuclide therapy (PRRT)—results and side-effects of the radioisotope 90 Y-DOTA TATE, 177 Lu-DOTA TATE or 90 Y/ 177 Lu-DOTA TATE therapy in patients with disseminated NET. Radiother Oncol . 2012;102:45–50.
Hirmas N, Jadaan R, Al-Ibraheem A. Peptide receptor radionuclide therapy and the treatment of gastroentero-pancreatic neuroendocrine tumors: current findings and future perspectives. Nucl Med Mol Imaging . 2018;52:190–199.
Marinova M, Mücke M, Mahlberg L, et al. Improving quality of life in patients with pancreatic neuroendocrine tumor following peptide receptor radionuclide therapy assessed by EORTC QLQ-C30. Eur J Nucl Med Mol Imaging . 2018;45:38–46.
Zandee WT, Brabander T, Blažević A, et al. Peptide receptor radionuclide therapy with 177 Lu-DOTATATE for symptomatic control of refractory carcinoid syndrome. J Clin Endocrinol Metab . 2021;106:e3665–e3672.
Bodei L, Cremonesi M, Grana CM, et al. Peptide receptor radionuclide therapy with 177 Lu-DOTATATE: the IEO phase I–II study. Eur J Nucl Med Mol Imaging . 2011;38:2125–2135.
Kwekkeboom DJ, Krenning EP. Peptide receptor radionuclide therapy in the treatment of neuroendocrine tumors. Hematol Oncol Clin North Am . 2016;30:179–191.
المشرفين على المادة: 0 (copper dotatate CU-64)
BRH40Y9V1Q (Lutetium-177)
0 (Radioisotopes)
0 (Receptors, Peptide)
تواريخ الأحداث: Date Created: 20221117 Date Completed: 20221123 Latest Revision: 20230203
رمز التحديث: 20240829
DOI: 10.1097/MPA.0000000000002101
PMID: 36395404
قاعدة البيانات: MEDLINE
الوصف
تدمد:1536-4828
DOI:10.1097/MPA.0000000000002101